Lilly cuts a $960m deal with Rigel on RIP kinase

Eli Lilly has become the latest drugmaker to have a go at developing RIP kinase inhibitors, a new class of drugs with potential in autoimmune and inflammatory disease, paying $125 million u

Vicore builds case for C21 drug in hospitalised COVID-19 pat...

Two weeks ago, Vicore reported mid-stage data showing that its lead drug C21 could boost the benefit of steroid therapy in treating COVID-19.

Phase 3 wins put Dermavant closer to filing Otezla rival tap...

Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of

Sanofi’s Dupixent backed for nasal polyps use in Europe

Next gen psoriasis drugs show superiority to Stelara

Guselkumab can also be used if older drug Stellara fails.